U.S. markets open in 3 hours 58 minutes

TransMedics Group, Inc. (TMDX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
22.90-0.74 (-3.13%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Short-term KST

Short-term KST

Previous Close23.64
Open23.00
Bid0.00 x 1000
Ask0.00 x 900
Day's Range22.30 - 23.35
52 Week Range10.10 - 24.77
Volume157,562
Avg. Volume100,480
Market Cap621.982M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.36
Earnings DateNov 04, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.20
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • TransMedics to Present at the 39th Annual J.P. Morgan Healthcare Conference
    PR Newswire

    TransMedics to Present at the 39th Annual J.P. Morgan Healthcare Conference

    TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today that members of the management team will present virtually at the upcoming 39th Annual J.P. Morgan Healthcare Conference. Management is scheduled to present on Wednesday, January 13, 2020 at 5:20 p.m. Eastern Standard Time.

  • TransMedics Appoints Merilee Raines to Board of Directors
    PR Newswire

    TransMedics Appoints Merilee Raines to Board of Directors

    TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today the appointment of Merilee Raines to its Board of Directors and as a member of the Audit Committee, effective January 1, 2021. The Board appointed Ms. Raines as Chair of the Audit Committee, effective as of June 1, 2021.

  • Is TMDX A Good Stock To Buy Now?
    Insider Monkey

    Is TMDX A Good Stock To Buy Now?

    The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 817 world-class investment firms that we track and now have access to the collective wisdom contained in […]